The use of procalcitonin in patients with surgical forms of erysipelas
Keywords:procalcitonin, surgical forms of erysipelas
The ideal marker of bacterial infection should not only allow for early diagnosis, but also provide information about the course and prognosis of the disease. Nowadays the most well-studied and widely used in clinical practice is procalcitonin (PCT), but its value in surgical forms of erysipelas is insufficiently defined. The aim of the article is to determine the diagnostic and prognostic significance of procalcitonin in patients with surgical forms of erysipelas.114 case histories of patients who were hospitalized in the center of purulent-septic surgery of the Non-profit municipal enterprise "City Hospital №3" in Zaporozhye for 2019-2020 period were analyzed retrospectively and prospectively. It was found that most often the focus was localized on the lower extremities. In the complex treatment of patients with erysipelas, the main place belongs to antibiotic therapy (ABT) and early surgical treatment of the area of the pathological process. Determination of the level of procalcitonin in the serum makes it possible to assess the progression and generalization of the process and is a sensitive test for the effectiveness of treatment.Radical surgery and timely targeted ABT are key elements of success in the treatment of surgical forms of erysipelas and are not subject to revision. Procalcitonin is a diagnostic marker that can predict the development of sepsis.
Gopatsa GV, Yermakova LA. [Erysipelas: current state of the problem]. Nauchnyi almanakh. 2016;1-2:364-41. Russian.
Gostishchev VK, Lipatov KV, Komarova YEA. [Streptococcal infection in surgery]. Khirurgiia. Zhurnal im. NI Pirogova. 2015;12:14-7. Russian. doi: https://doi.org/10.17116/hirurgia20151214-17
Polyakova AS, et al. [The diagnostic value of determining the level of procalcitonin in the practice of an infectious disease specialist]. Voprosy sovremennoi pediatrii. 2017;16:334-41. Russian. doi: https://doi.org/10.15690/vsp.v16i4.1781
[Electronic textbook on statistics]. [Internet]. [cited 2019 July 01]. Ukrainian. Available from: http://statsoft.ru/home/textbook/default.htm
Ratnikova LI, et al. [Comorbidity of erysipelas and endocrine diseases]. Nauchnyi almanakh. 2016;3:341-6. Russian. doi: https://doi.org/10.17117/na.2016.05.03.341
Vitik AA, et al. [Predictors of the development of sepsis and septic shock]. Vestnik intensivnoi terapii. 2017;3:63-8. Russian. Available from: https://intensive-care.ru/prediktory-razvitiya-sepsisa-i-septicheskogo-shoka/
Seymour CW, Liu V, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis. JAMA. 2016;315(8):762-44. doi: https://doi.org/10.1001/jama.2016.0288
Bruun Т. Early response in cellulitis: a prospective study of dynamics and predictors. Clinical Infectious Diseases. 2016;63(8):1034-41. doi: https://doi.org/10.1093/cid/ciw463
De Jong JA, Van Oers А. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious Diseases. 2016;7:1-9.
Falconeet М. Acute bacterial skin and skin structure infection sininternal medicine wards: old and new drugs. Internaland Emergency Medicine. 2016;11(5):637-48.
Milcent K. Use of Procalciton in Assaysto Predict Serious Bacterial Infectionin Young Febrile Infants. JAMA Pediatr. 2016;170(1):62-69. doi: https://doi.org/10.1001/jamapediatrics.2015.3210
Singer M. Third International Consensus Definitions for Sepsis and Septic Shock). JAMA. 2016;315(8):801-10. doi: https://doi.org/10.1001/jama.2016.0287
Rhodes A, Evans LE, Alhazzani Waleed, Mitchell M Levy, Massimo A, Ferrer R., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. [Internet]. 2017 Mar;43(3):304-77. doi: https://doi.org/10.1007/s00134-017-4683-6
How to Cite
Copyright (c) 2021 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.